Regulus notches another microRNA deal in pact with Biogen Idec

Fast on the heels of a $28 million partnership with AstraZeneca ($AZN), Regulus Therapeutics has struck again with another marquee microRNA pact--this time with Biogen Idec ($BIIB). The release doesn't spell out the upfront and milestone dollars attached to this deal, but Regulus will put its technology to work to find microRNA biomarkers for multiple sclerosis, a big franchise for the Biogen folk. "Utilizing innovative technology such as biomarkers can help us make more informed decisions earlier in clinical development and is key to our overall company strategy to enhance early-stage discovery efforts," said Steven Holtzman, Biogen's chief deal-maker. Release